The Effect of Soluble Epoxide Hydrolase (SEH) on Depression

Last updated: November 14, 2024
Sponsor: Nanfang Hospital, Southern Medical University
Overall Status: Completed

Phase

N/A

Condition

Mood Disorders

Depression

Depression (Major/severe)

Treatment

N/A

Clinical Study ID

NCT05575713
NFEC-2022-092
  • Ages 18-65
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

Depression is the most common mental disease and the second leading cause of chronic disease burden, which is closely related to suicidal behavior. The diagnosis and treatment of depression still lack of effective biological indicators, and about 30% of patients with depression still can not relieve their depressive symptoms after treatment. Previous studies have found that ATP release from astrocytes plays an important role in the occurrence, development and treatment of depression. Epoxy eicosotrienes (eets) are closely related to the function of the nervous system and may be the pathophysiological mechanism of depression. Soluble epoxide hydrolase (SEH) can regulate ATP release by affecting EET degradation, leading to depression like behavior and antidepressant effect, and sEH is closely related to cognitive function of depression.

Eligibility Criteria

Inclusion

  • Inclusion criteria:

  1. Voluntarily sign informed consent;

  2. Age: 18-65 years old;

  3. Elementary school or above, able to understand and complete all inspections andassessments;

  4. Did not take any psychotropic drugs (including benzodiazepines) within 2 weeksbefore enrollment;

  5. After routine medical diagnosis by clinicians, they were divided intodepression and healthy people.

Exclusion

  • Exclusion criteria:

  1. Severe somatic or neurological diseases;

  2. Mental retardation and dementia;

  3. During pregnancy or breastfeeding;

  4. Heavy smoking, alcoholism and other substance abuse or dependence (within 3months before enrollment);

  5. Electric shock treatment (within 3 months before enrollment);

  6. According to the judgment of the investigator, it is not suitable toparticipate in this study.

Study Design

Total Participants: 330
Study Start date:
June 01, 2019
Estimated Completion Date:
October 31, 2024

Study Description

This study is an observational study without any intervention treatment for the subjects. All subjects need to sign the informed consent before screening, and the successful subjects can enter the study. Routine clinical diagnosis and treatment were performed on patients with depression, and the treatment effect of depressive symptoms, neurocognitive function and suicide improvement were evaluated at the 2nd week, 1st, 2nd, 3rd, 6th and 12th months after enrollment, and statistical analysis was conducted. The treatment lasted until the subjects completed the 12th month follow-up or reached any of the withdrawal criteria. This study will clarify the relationship between sEH gene polymorphism and mRNA expression and depression and suicide behavior, and explore the predictive role of soluble epoxide hydrolase sEH in the treatment effect of depression, cognition and suicide improvement during the follow-up study.

Connect with a study center

  • Nanfang Hospital, Southern Medical University

    Guangzhou, Guangdong 510515
    China

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.